Why Should You Attend:
This 3-hr virtual seminar will provide an introduction to the U.S. Food and Drug Administration’s regulation of cell therapies and other HCT/Ps for human use. It will cover several topics including who is responsible for the regulation of cell and gene therapies in the U.S., how such therapies are regulated, and explore the various regulatory criteria against which these therapies are distinguished.
The presenter will also discuss product labeling, FDA inspections and the potential enforcement risks associated with the marketing and sale of such therapies in the U.S. today. Attendees will also be provided with an overview of FDA’s current enforcement activities in the areas of cell and gene therapies, and HCT/Ps generally.
By participating in this webinar, an attendee will gain an understanding of
Areas Covered in the Seminar:
Who will Benefit:
Karl M. Nobert, is an accomplished attorney with knowledge of and experience with the U.S. Food and Drug Administration’s regulation of regenerative medicine including cell therapies and HCT/Ps, prescription and over-the-counter drug products, food, biologics, medical devices and veterinary products. Mr. Nobert possesses a considerable understanding of and experience dealing with the FDA’s regulation of human and veterinary regenerative medicine therapies and products including the FDA’s regulation of such products, the commercialization of cell therapies, the marketing and sale of stem cell-based products intended for human use; and the introduction of veterinary cell therapies to the market. He frequently presents and publishes on the subject, and currently services as Legal Advisor to an international consortium of stem cell researchers and firms.
Stem cells intended for therapeutic purposes in humans are regulated by the U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research (“CBER”) under the Agency’s regulations governing the use of human cells, tissues, and cellular and tissue-based products (“HCT/Ps”). These regulations define HCT/Ps as “articles containing or consisting of human cells or tissues that are intended for implantation, transplantation, infusion, or transfer into a human recipient.”
FDA’s regulations include provisions governing registration and listing requirements for establishments that manufacture and process HCT/Ps; provisions discussing donor eligibility; recommended current good tissue practices covering all stages of production, including harvesting, processing, manufacture, storage, labeling, packaging, and distribution; and other requirements intended to prevent the introduction, transmission, and spread of communicable diseases in humans.
FDA’s regulatory approach to cell therapies and other HCT/Ps is based on an established drug / non-drug comparison that is made on the basis of an established “minimal manipulation” standard. Depending on the level of manipulation involved in the production process and a product’s ultimate intended use, such a product could be regulated as simply an HCT/P or something entirely more complex such as a licensed biologic, an approved drug product or a medical device.
From a regulatory perspective, there are also various labeling and promotional considerations that a firm must be aware of when marketing a cell therapy in the U.S. Over the past few years, a lack of awareness of such rules by some companies has resulted in FDA enforcement action.
This presentation will provide participants with an overview of who regulated cell therapies and other HCT/Ps in the U.S. today. It will also provide an introduction to the regulatory criteria that FDA applies when governing such products. The presentation will examine current FDA labeling rules, will provide recommendations for preparing for an Agency inspection and will offer strategies for mitigating potential enforcement risks.
Our refund policy is governed by individual products and services refund policy mentioned against each of offerings. However in absence of specific refund policy of an offering below refund policy will be effective.
Registrants may cancel up to two working days prior to the course start date and will receive a letter of credit to be used towards a future course up to one year from date of issuance. ComplianceOnline would process/provide refund if the Live Webinar has been cancelled. The attendee could choose between the recorded version of the webinar or refund for any cancelled webinar. Refunds will not be given to participants who do not show up for the webinar. On-Demand Recordings can be requested in exchange. Webinar may be cancelled due to lack of enrolment or unavoidable factors. Registrants will be notified 24hours in advance if a cancellation occurs. Substitutions can happen any time. On-Demand Recording purchases will not be refunded as it is available for immediate streaming. However if you are not able to view the webinar or you have any concern about the content of the webinar please contact us at below email or by call mentioning your feedback for resolution of the matter. We respect feedback/opinions of our customers which enables us to improve our products and services. To contact us please email [email protected] call +1-888-717-2436 (Toll Free).
PAYMENT METHOD: 100% Secure Transaction